Abstract
The classical actions of parathyroid hormone (PTH) are well recognized, but its effects on other target tissues, such as the cardiovascular system, are less appreciated. Several studies have evaluated the effects of PTH in patients with primary hyperparathyroidism in order to understand potential cardiovascular effects in terms of hypertension, cardiovascular mortality, left ventricular function, and endothelial function. We review these studies and evaluate the cellular mechanisms that may affect these outcomes.
Similar content being viewed by others
References
Ljunghall S, Abela C, Frank H, et al.: Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997, 82:106–112.
Hedback GM, Oden AS: The influence of surgery on the risk of death in patients with hyperparathyroidism. World J Surg 1998, 15:399–405.
Palmer M, Adami HO, Bergstrom R, Akerstrom G: Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery 1987, 102:1–7.
Wermers RA, Khosla S, Atkinson EJ, et al.: Survival after the diagnosis of hyperparathyroidism: a population-based study. Am J Med 1998, 104:115–122.
Vestergaard H, Ostergaard Kristensen L: Normocalcemia and persistent elevated serum concentrations of 1–84 parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of increased morbidity from cardiovascular disease. World J Surg 2002, 26:657–660.
Ogard CG, Engholm MS, Almdal TP, Vestergaard H: Increased mortality in patients hospitalized with primary hyperparathyroidism during the period 1977-1993 in Denmark. World J Surg 2004, 28:108–111.
Kamycheva E, Sundsfjord J, Jorde R: Serum parathyroid hormone levels predict coronary heart disease: the Tromsø Study. Eur J Cardiovasc Prev Rehabil 2004, 11:69–74.
Lind L, Skarfors E, Berglund L, et al.: Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol 1997, 50:967–973.
Jorde R, Sundsfjord J, Fitzgerald P, Bonaa KH: Serum calcium and cardiovascular risk factors and diseases: the Tromsø study. Hypertension 1999, 34:484–490.
Leifsson BG, Ahren B: Serum calcium and survival in a large health-screening program. J Clin Endocrinol Metab 1996, 81:2149–2153.
Rubin MR, Rundek T, McMahon DJ, et al.: Carotid artery plaque thickness is associated with increased serum calcium levels: the Northern Manhattan study. Atherosclerosis 2007, 194:426–432.
Barletta G, De Feo ML, Del Bene R, et al.: Cardiovascular effects of parathyroid hormone: a study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000, 85:1815–1821.
Snijder MB, Lips P, Seidell JC, et al.: Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med 2007, 261:558–565.
Jorde R, Sundsfjord J, Haug E, Bønaa KH: Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension 2000, 35:1154–1159.
Morfis L, Smerdely P, Howes LG: Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens 1997, 15:1271–1276.
Hulter HN, Melby JC, Peterson JC, Cooke CR: Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens 1998, 2:360–370.
Fliser D, Franek E, Fode P, et al.: Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997, 12:933–938.
Nilsson IL, Aberg J, Rastad J, Lind L: Maintained normalization of cardiovascular dysfunction 5 years after parathyroidectomy in primary hyperparathyroidism. Surgery 2005, 137:632–638.
Schleiffer R: Parathyroid hormone and genetic hypertension. Int J Cardiol 1992, 35:303–310.
Sancho JJ, Rouco J, Riera-Vidal R, Sitges-Serra A: Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg 1992, 16:732–735.
Nilsson IL, Rastad J, Johansson K, Lind L: Endothelial vasodilatatory function and blood pressure response to local and systemic hypercalcemia. Surgery 2001, 130:986–990.
Gennari C, Nami R, Gonnelli S: Hypertension and primary hyperparathyroidism: role of the adrenergic and plasma renin angiotensin systems. Miner Electrolyte Metab 1995, 21:77–81.
Lakatos P, Tatra A, Foldes J, et al.: Endothelin concentrations are elevated in plasma of patients with primary and secondary hyperparathyroidism. Calcif Tissue Int 1996, 58:70–71.
Sangal AK, Kevwitch M, Rao DS, Rival J: Hypomagnesemia and hypertension in primary hyperparathyroidism. South Med J 1989, 82:1116–1118.
Almqvist EG, Bondeson AG, Bondeson L, et al.: Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy. Surgery 2002, 132:1126–1132.
Stefenelli T, Abela C, Frank H, et al.: Cardiac abnormalities in patients with primary hyperparathyroidism: implications for follow-up. J Clin Endocrinol Metab 1997, 82:106–112.
Piovesan A, Molineri N, Casasso F, et al.: Left ventricular hypertrophy in primary hyperparathyroidism: effects of successful parathyroidectomy. Clin Endocrinol (Oxf) 1999, 50:321–328.
Nilsson IL, Aberg J, Rastad J, Lind L: Left ventricular systolic and diastolic function and exercise testing in primary hyperparathyroidism—effects of parathyroidectomy. Surgery 2000, 128:895–902.
Ogard CG, Sondergaard SB, Vestergaard H, et al.: Myocardial perfusion defects and the left ventricular ejection fraction disclosed scintigraphy in patients with primary hyperparathyroidism. World J Surg 2005, 29:914–916.
Baykan M, Erem C, Erdogan T, et al.: Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism. Int J Cardiovasc Imaging 2007, 23:323–328.
Kosch M, Hausberg M, Vormbrock K, et al.: Impaired flow-mediated vasodilatation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 2000, 47:813–818.
Dipette DJ, Christenson W, Nickols MA, Nickols GA: Cardiovascular responsiveness to parathyroid hormone (PTH) and PTH-related protein in genetic hypertension. Endocrinology 1992, 130:2045–2051.
Schluter KD, Piper HM: Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Circ Res 1998, 37:34–41.
Bogin E, Massry SG, Harary I: Effects of parathyroid hormone on rat heart cell. J Clin Invest 1981, 67:1215–1227.
Roca-Cusachs A, Dipette DJ, Nickols G: Regional and systemic hemodynamic effects of parathyroid hormone-related protein: preservation of cardiac function and coronary and renal flow with reduced blood pressure. J Pharmacol Exp Ther 1991, 256:110–118.
Tenner TE Jr, Ramanadham S, Yang MC, Pang PK: Chronotropic actions of bPTH-(1–34) in the right atrium of the rat. Can J Physiol Pharmacol 1983, 61:1162–1167.
Smogorzewski M, Zayed M, Zhang YB, et al.: Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol Heart Circ Physiol 1993, 264:H1998–H2006.
Hara M, Liu Y, Zhen L, et al.: The positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are due to increases in the current I(f), and the slope of the pacemaker potential. Circulation 1997, 96:3704–3709.
Nickols GA, Nana AD, Nickols MA, et al.: Hypotension and cardiac stimulation due to the parathyroid hormone-related protein, humoral hypercalcemia of malignancy factor. Endocrinology 1989, 125:834–841.
Hara M, Liu YM, Zhen L, et al.: Positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are associated with increases in the current, I(f), and the slope of the pacemaker potential. Circulation 1997, 96:3704–3709.
Shimoyama M, Ogino K, Burkhoff D, et al.: Signal transduction pathways and the chronotropic actions of PTH in isolated rat hearts [abstract P-592]. Presented at the 80 th Annual Meeting of the Endocrine Society. New Orleans, LA; June 23–27, 1998.
Shimoyama M, Ogino K, Taniguchi S, et al.: Signal transduction pathways and chronotropic actions of PTH and its fragments in isolated, perfused rat hearts. Bone 1998, 23(Suppl 5):T197.
Ogino K, Burkhoff D, Bilezikian JP: The hemodynamic basis for the cardiac effects of parathyroid hormone (PTH) and PTH-related protein. Endocrinology 1995, 136:3024–3030.
Smith JC, Page MM, John R, et al.: Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000, 85:3515–3519.
Rubin MR, Maurer MS, McMahon DJ, et al.: Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrin Metabol 2005, 90:3326–3330.
Nilsson IL, Aberg J, Rastad J, Lind L: Circadian cardiac autonomic nerve dysfunction in primary hyperparathyroidism improves after parathyroidectomy. Surgery 2003, 134:1013–1019.
Nuzzo V, Tauchmanova L, Fonderico F, et al.: Increased intima-media thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol 2002, 147:453–459.
Fallo F, Cella G, Casonato A, et al.: Biochemical markers of endothelial activation in primary hyperparathyroidism. Horm Metab Res 2006, 38:125–129.
Rashid G, Bernheim J, Green J, et al.: Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol Dial Transplant 2007, 22:2831–2837.
Nyby MD, Hino T, Berger ME, et al.: Desensitization of vascular tissue to parathyroid hormone and parathyroid hormone-related protein. Endocrinology 1995, 136:2497–2504.
Chadwick DR, Harrison BJ, Chan P, et al.: Vasoactive and proliferative effects of parathyroid hormone and parathyroid hormone-related peptide on human vascular smooth muscle. Br J Surg 2000, 87:1529–1533.
Somjen D, Weisman Y, Kohen F, et al.: 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005, 111:1666–1671.
Perkovic V, Hewitson TD, Kelynack KJ, et al.: Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney Blood Press Res 2003, 26:27–33.
Whitfield JF: Osteogenic PTHs and vascular ossification—is there a danger for osteoporotics? J Cell Biochem 2005, 95:437–444.
Jono S, Nishizawa Y, Shioi A, et al.: Parathyroid hormone-related peptide as a local regulator of vascular calcification. Arterioscler Thromb Vasc Biol 1997, 17:1135–1142.
Ogard CG, Engelmann MD, Kistorps C, et al.: Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol 2005, 63:493–498.
Delfini E, Petramala L, Caliumi C, et al.: Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 2007, 56:30–36.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fitzpatrick, L.A., Bilezikian, J.P. & Silverberg, S.J. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 6, 77–83 (2008). https://doi.org/10.1007/s11914-008-0014-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11914-008-0014-8